GWM
PBE icon

Geneos Wealth Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Geneos Wealth Management’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100
Closed -$5K – 2534
2019
Q2 		$5K Sell
100
-300
-75% -$15.6K ﹤0.01% 2122
2019
Q1 		$22K Buy
400
+300
+300% +$15.9K ﹤0.01% 1532
2018
Q4 		$4K Hold
100
– – ﹤0.01% 2060
2018
Q3 		$5K Hold
100
– – ﹤0.01% 2066
2018
Q2 		$5K Buy
+100
New +$5.08K ﹤0.01% 1923

Other funds holding PBE

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PA
PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

Geneos Wealth Management's PBE Position: Q3 2019 in Review

Geneos Wealth Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2019, closing a stake of 100 shares — an estimated $5K sold.

Geneos Wealth Management first reported a position in PBE in Q2 2018 and held it in 5 quarters. The position peaked at $22K in Q1 2019. 73 funds tracked by Wall St. Rank hold PBE as of Q3 2019.

  • Geneos Wealth Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2019 after selling out during the quarter.
  • Geneos Wealth Management sold 100 Invesco Biotechnology & Genome ETF shares in Q3 2019, an estimated $5K.
  • Geneos Wealth Management first reported a position in Invesco Biotechnology & Genome ETF in Q2 2018 and held it in 5 quarters.
  • Geneos Wealth Management's Invesco Biotechnology & Genome ETF position peaked at $22K in Q1 2019.
  • 73 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2019.

Based on Geneos Wealth Management's 13F filing for Q3 2019, filed 7 Sep 2021.